Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy

H. J. Lee, B. Oran, R. M. Saliba, D. M. Couriel, K. Shin, P. Massey, J. Neumann, M. de Lima, R. Champlin, S. Giralt

Research output: Contribution to journalArticle

33 Scopus citations


High-dose steroids are the first line of treatment for acute graft-versus-host disease (aGVHD). Steroid myopathy is a debilitating steroid-induced complication that significantly impairs a patient's performance status. To determine the frequency and severity of steroid myopathy and other steroid related complications in patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) who developed grade ≥2 aGVHD after allogeneic hematopoietic stem cell transplantation (HSCT), we performed a retrospective analysis. Patients were included in the analysis if they had a diagnosis of AML/MDS, underwent an allogeneic HSCT between January 1996 and December 2001 and developed grade ≥2 aGVHD that was treated with 2mg/kg of methylprednisolone and survived at least 100 days post transplant. A total of 70 patients fulfilled our inclusion criteria. Steroid myopathy was identified in 29 (41%) patients. Steroid myopathy was generally of moderate severity with severe debilitating steroid myopathy seen in only 3% of patients. We concluded that steroid myopathy is a common complication of high-dose steroid therapy after allogeneic HSCT in AML/ MDS. Interventions aimed at preventing and treating this complication are warranted and need to be explored in prospective clinical trials.

Original languageEnglish (US)
Pages (from-to)299-303
Number of pages5
JournalBone marrow transplantation
Issue number4
StatePublished - Aug 1 2006

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy'. Together they form a unique fingerprint.

  • Cite this